HEPA, PM2.5, and Cardiometabolic Health
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-84
SponsorUniversity of Southern California
About this trial
The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.
Eligibility criteria
Qualifiers
Age between 65 and 84 years old;
Nonsmoker for at least 1 year;
History of BMI ≥ 25 kg/m2 in the past based on EMR information;
Either an English or Spanish speaker;
Disqualifiers
History of diabetes (both type 1 and type 2) or degenerative disease of the nervous system (Alzheimer's disease or dementia);
Currently have active cancer treatment;
The residential house has already had HEPA filters;
Participants will move out of the current house in the next 2 years;
Trial design
Treatments tested in this trial
- HEPA filter
- Sham filter
Treatment groups
52 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Southern California
Lead sponsor
Duke University
Collaborator
Source ClinicalTrials.gov